Yahoo Canada Web Search

Search results

1. finance.yahoo.com › news › state-street-corpsState Street Corp's Strategic Acquisition in Beam ...

   finance.yahoo.com › news › state-street-corps

   • Cached

   2 days ago · On September 30, 2024, State Street Corp made a significant addition to its investment portfolio by acquiring 3,929,557 shares of Beam Therapeutics Inc (NASDAQ:BEAM), a pioneering biotechnology ...

   • Beam Therapeutics Inc. (BEAM) Stock Price, News, Quote ...

     RXRX Recursion Pharmaceuticals, Inc. 6.55. -6.56%. Find the...

   • What Makes Beam Therapeutics Inc. (BEAM) a New Buy Stock

     The upgrade of Beam Therapeutics Inc. to a Zacks Rank #2...

2. www.gurufocus.com › news › 2558076State Street Corp's Strategic Acquisition in Beam Therapeutics I

   www.gurufocus.com › news › 2558076

   • Cached

   On September 30, 2024, State Street Corp made a significant addition to its investment portfolio by acquiring 3,929,557 shares of Beam Therapeutics Inc (BEAM, Financial), a pioneering biotechnology company. This transaction, executed at a price of $24.5 per share, reflects State Street Corp's strategic approach to investing in high-potential sectors.

3. finance.yahoo.com › quote › BEAMBeam Therapeutics Inc. (BEAM) Stock Price, News, Quote ...

   finance.yahoo.com › quote › BEAM

   • Cached

   RXRX Recursion Pharmaceuticals, Inc. 6.55. -6.56%. Find the latest Beam Therapeutics Inc. (BEAM) stock quote, history, news and other vital information to help you with your stock trading and ...

4. seekingalpha.com › article › 4724004-beamBeam Therapeutics: Still Holding Fast To Generous Valuation ...

   seekingalpha.com › article › 4724004-beam

   Sep 29, 2024 · Beam Therapeutics' pipeline, including BEAM-101, BEAM-201, and BEAM-302, shows promise but remains in early stages with no clinical trial data yet available. Despite a strong cash position, Beam's ...

5. finance.yahoo.com › news › makes-beam-therapeuticsWhat Makes Beam Therapeutics Inc. (BEAM) a New Buy Stock

   finance.yahoo.com › news › makes-beam-therapeutics

   • Cached

   Nov 17, 2023 · The upgrade of Beam Therapeutics Inc. to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the ...

6. edition.cnn.com › markets › stocksBEAM Stock Quote Price and Forecast | CNN - CNN International

   edition.cnn.com › markets › stocks

   • Cached

   Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered ...

7. People also ask

   Why did State Street buy Beam Therapeutics Inc?

   • On September 30, 2024, State Street Corp made a significant addition to its investment portfolio by acquiring 3,929,557 shares of Beam Therapeutics Inc (NASDAQ:BEAM), a pioneering biotechnology company. This transaction, executed at a price of $24.5 per share, reflects State Street Corp's strategic approach to investing in high-potential sectors.

   State Street Corp's Strategic Acquisition in Beam Therapeutics Inc

   finance.yahoo.com/news/state-street-corps-strategic-acquisition-190516217.html

   See all results for this question

   Should you buy Beam Therapeutics (beam)?

   • Beam Therapeutics' pipeline, including BEAM-101, BEAM-201, and BEAM-302, shows promise but remains in early stages with no clinical trial data yet available. Despite a strong cash position, Beam's high valuation suggests heavy speculation and high expectations, leading to potential volatility in stock performance.

   Beam Therapeutics: Still Holding Fast To Generous Valuation, Still Not …

   seekingalpha.com/article/4724004-beam-therapeutics-still-holding-fast-to-generous-valuation-still-not-a-buy

   See all results for this question

   Will Beam Therapeutics (beam) stock gain in Q4?

   • Beam Therapeutics (BEAM) stock gains as the company reports profits in Q4 after boosting revenue thanks to a collaboration deal with Eli Lilly (LLY). Read more here.

   Beam stock jumps as Eli Lilly deal drives Q4 beat

   seekingalpha.com/news/4072415-beam-stock-jumps-as-eli-lilly-deal-brings-q4-beat

   See all results for this question

   Where is Beam Therapeutics headquartered?

   • The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA. View Beam Therapeutics, Inc. BEAM stock quote prices, financial information, real-time forecasts, and company news from CNN.

   BEAM Stock Quote Price and Forecast | CNN

   edition.cnn.com/markets/stocks/BEAM

   See all results for this question

   Why did Beam Therapeutics (beam) reach a 52-week high?

   • Shares of Beam Therapeutics ( NASDAQ: BEAM) reached a 52-week high on Tuesday after the gene-editing company swung to profits in Q4, exceeding Wall Street projections as its revenue jumped thanks to a collaboration agreement with Eli Lilly ( LLY ).

   Beam stock jumps as Eli Lilly deal drives Q4 beat

   seekingalpha.com/news/4072415-beam-stock-jumps-as-eli-lilly-deal-brings-q4-beat

   See all results for this question

   Is beam a biotechnology company?

   • Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201.

   BEAM Stock Quote Price and Forecast | CNN

   edition.cnn.com/markets/stocks/BEAM

   See all results for this question

8. seekingalpha.com › news › 4072415-beam-stock-jumpsBeam stock jumps as Eli Lilly deal drives Q4 beat - Seeking Alpha

   seekingalpha.com › news › 4072415-beam-stock-jumps

   Feb 27, 2024 · Beam Therapeutics (BEAM) stock gains as the company reports profits in Q4 after boosting revenue thanks to a collaboration deal with Eli Lilly (LLY). Read more here.